title: Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study.
abstract: BACKGROUND
  The relationship between neutrophils and outcomes post-myocardial infarction (MI) is not completely characterized. We examined the associations of neutrophil count with mortality and post-MI heart failure (HF) and their incremental value for risk discrimination in the community.
  
  
  RESULTS
  MI was diagnosed with cardiac pain, biomarkers, and Minnesota coding of the ECG. Neutrophil count at presentation, reported as counts x10(9)/L, was categorized by tertiles (lower tertile, <5.7; middle tertile, 5.7 to 8.5; upper tertile, >8.5). From 1979 to 2002, 2047 incident MIs occurred in Olmsted County, Minn (mean age, 68+/-14 years; 44% women). Median (25th to 75th percentile) neutrophil count was 7.0 (5.1 to 9.5). Within 3 years post-MI, 577 patients died, and 770 developed HF. Overall survival and survival free of HF decreased with increased neutrophil tertile (P<0.001). Compared with the lower tertile, the age and sex adjusted hazard ratio for death was 1.44 (95% CI, 1.14 to 1.81) for the middle tertile and 2.60 (95% CI, 2.10 to 3.22) for the upper tertile (P<0.001). Similarly, for HF, the hazard ratio was 1.32 (95% CI, 1.09 to 1.59) for the middle and 2.12 (95% CI, 1.77 to 2.53) for the upper tertile (P<0.001). These associations persisted after adjustment for risk factors, comorbidities, Killip class, revascularization, and ejection fraction. Neutrophil count improved risk discrimination as indicated by increases in the area under the receiver operating characteristic curves (all P<0.05) and by the integrated discrimination improvement analysis (all P<0.001).
  
  
  CONCLUSIONS
  In the community, the neutrophil count was strongly and independently associated with death and HF post-MI and improved risk discrimination over traditional predictors.
authors.affiliation: Division of Cardiovascular Diseases and Internal Medicine and the Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
authors.forename: Adelaide M
authors.initials: AM
authors.lastname: Arruda-Olson
authors.forename: Guy S
authors.initials: GS
authors.lastname: Reeder
authors.forename: Malcolm R
authors.initials: MR
authors.lastname: Bell
authors.forename: Susan A
authors.initials: SA
authors.lastname: Weston
authors.forename: Véronique L
authors.initials: VL
authors.lastname: Roger
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D015992:Body Mass Index; D002452:Cell Count; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000453:epidemiology; D005260:Female; D006333:Heart Failure / Q000453:epidemiology*; D006760:Hospitalization; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000453:epidemiology; D007239:Infections / Q000453:epidemiology; D008297:Male; D008910:Minnesota / Q000453:epidemiology; D009203:Myocardial Infarction / Q000401:mortality*; D009204:Myocardial Revascularization; D009504:Neutrophils / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016016:Proportional Hazards Models; D012372:ROC Curve; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000319:Adrenergic beta-Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin